Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain R K
Department of Radiation Oncology, Massachusetts General Hospital, Boston, USA.
Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14765-70. doi: 10.1073/pnas.93.25.14765.
The hyperpermeability of tumor vessels to macromolecules, compared with normal vessels, is presumably due to vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) released by neoplastic and/or host cells. In addition, VEGF/VPF is a potent angiogenic factor. Removal of this growth factor may reduce the permeability and inhibit tumor angiogenesis. To test these hypotheses, we transplanted a human glioblastoma (U87), a human colon adenocarcinoma (LS174T), and a human melanoma (P-MEL) into two locations in immunodeficient mice: the cranial window and the dorsal skinfold chamber. The mice bearing vascularized tumors were treated with a bolus (0.2 ml) of either a neutralizing antibody (A4.6.1) (492 micrograms/ml) against VEGF/VPF or PBS (control). We found that tumor vascular permeability to albumin in antibody-treated groups was lower than in the matched controls and that the effect of the antibody was time-dependent and influenced by the mode of injection. Tumor vascular permeability did not respond to i.p. injection of the antibody until 4 days posttreatment. However, the permeability was reduced within 6 h after i.v. injection of the same amount of antibody. In addition to the reduction in vascular permeability, the tumor vessels became smaller in diameter and less tortuous after antibody injections and eventually disappeared from the surface after four consecutive treatments in U87 tumors. These results demonstrate that tumor vascular permeability can be reduced by neutralization of endogenous VEGF/ VPF and suggest that angiogenesis and the maintenance of integrity of tumor vessels require the presence of VEGF/VPF in the tissue microenvironment. The latter finding reveals a new mechanism of tumor vessel regression-i.e., blocking the interactions between VEFG/VPF and endothelial cells or inhibiting VEGF/VPF synthesis in solid tumors causes dramatic reduction in vessel diameter, which may block the passage of blood elements and thus lead to vascular regression.
与正常血管相比,肿瘤血管对大分子的高通透性可能是由于肿瘤细胞和/或宿主细胞释放的血管内皮生长因子/血管通透因子(VEGF/VPF)所致。此外,VEGF/VPF是一种强大的血管生成因子。去除这种生长因子可能会降低通透性并抑制肿瘤血管生成。为了验证这些假设,我们将人胶质母细胞瘤(U87)、人结肠腺癌(LS174T)和人黑色素瘤(P-MEL)移植到免疫缺陷小鼠的两个部位:颅窗和背部皮褶小室。对患有血管化肿瘤的小鼠,用一剂(0.2 ml)抗VEGF/VPF的中和抗体(A4.6.1)(492微克/毫升)或PBS(对照)进行治疗。我们发现,抗体治疗组中肿瘤血管对白蛋白的通透性低于匹配的对照组,并且抗体的作用是时间依赖性的,且受注射方式的影响。直到治疗后4天,肿瘤血管通透性才对腹腔注射抗体产生反应。然而,静脉注射相同量的抗体后6小时内通透性就降低了。除了血管通透性降低外,抗体注射后肿瘤血管直径变小且迂曲程度减轻,在U87肿瘤连续四次治疗后,肿瘤血管最终从表面消失。这些结果表明,内源性VEGF/VPF的中和可降低肿瘤血管通透性,并提示血管生成和肿瘤血管完整性的维持需要组织微环境中存在VEGF/VPF。后一发现揭示了肿瘤血管消退的一种新机制,即阻断实体瘤中VEFG/VPF与内皮细胞之间的相互作用或抑制VEGF/VPF合成会导致血管直径显著减小,这可能会阻碍血液成分的通过,从而导致血管消退。